

PTO/PCT Rec'd 27 DEC 2000

Atty. Dkt. No. 028622/0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7

Applicant: Bernd DORKEN et al.
Title: NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES
AND USES THEREOF.
Appl. No.: 09/673,735
Filing Date: December 27, 2000
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

CONCISE EXPLANATION OF
RELEVANCE OF EACH DOCUMENT

Documents A1 – A10 came to Applicants' attention during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Documents A11 – A16 were mentioned in a response, dated May 16, 2000, to a Written Opinion issued by the European Patent Office acting as the IPEA on February 17, 2000, concerning the International application.

English translations of Documents A1 and A12 are not readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP§603). An English language summary is included with Document A12.

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

Date 27 December 2000

By Stephen A. Bent

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 028622/0102	SERIAL NO. 09/673,735
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Bernd DORKEN et al.	
		FILING DATE December 27, 2000	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A1 ✓	195 31 348	2/27/97	Fed. Republic of Germany				X
	A2 ✓	0 505 908	9/30/92	Europe				
	A3 ✓	91/09968	7/11/91	WIPO				
	A4 ✓	95/11922	5/4/95	WIPO				
	A5 ✓	96/36360	11/21/96	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A6 ✓	H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. 35, March, 1994, pg. 510, XP-002076122, abstract.
	A7 ✓	Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997
	A8 ✓	Sergey M. Kipriyanov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-002115487, Wiley-Liss, Inc., 1998
	A9 ✓	P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997
	A10 ✓	Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40th Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract.

EXAMINER	DATE CONSIDERED
----------	-----------------

* **EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

